Pharmaceutical 6105 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

NY invests $200 million to fight opioid, heroin abuse

Opioid abuse - Shutterstock

New York will invest more than $200 million to fight opioid and heroin abuse in the state, Gov. Andrew Cuomo said. The announcement adds more fuel to efforts the governor made last year to quell the growing opioid epidemic, including launching the Heroin and Opioid Task Force, increasing access to treatment, expanding community prevention strategies, and limiting overprescribing of opioids in the state. While “significant progress” has been made to curb the abuse and misuse of the powerful painkillers in New York, Cuomo said the comprehensive investment will address each component of heroin and opioid addiction, including prevention, treatment and ... Read More

J&J buys out Irish medtech company


One of Johnson & Johnson’s subsidiaries has snapped up Irish medtech company Neuravi in a deal that could be worth hundreds of millions of dollars. The consumer health care products and pharmaceutical giant’s DePuy Ireland subsidiary, an affiliate of Johnson & Johnson’s neurosurgery firm, Codman Neuro, purchased the company for an undisclosed sum. Neuravi manufactures a medical device called the EmboTrap that is used to retrieve blood clots in the brain following a stroke in order to restore blood flow to the vein. The device is used in the treatment of acute ischemic strokes, or blockages in the vessels supplying blood ... Read More

Jellyfish protein supplement maker defends memory boosting benefits in court

brain STEPS image

Wisconsin-based Quincy Bioscience told a New York federal court that its advertisements promoting the memory boosting effects of a jellyfish protein are not false or misleading because they are based on the Federal Trade Commission’s (FTC) “gold standard of scientific testing.” The company is facing claims by the FTC and the New York Attorney General’s Office that the company’s cited studies are not valid because they use specific subgroups. Quincy Bioscience argued that it referenced placebo-controlled, double-blind studies to prove the jellyfish protein offered cognitive benefits to users. Quincy Bioscience’s jellyfish protein is sold under the name brand Prevagen and ... Read More

Maker of diet pill tries to skirt criminal, civil charges

bathroom scale, diet, weight

Three years ago the diet pill OxyELITE Pro was blamed for two deaths, three liver transplants and about 50 hospitalizations for liver failure and other health issues in Hawaii. Now the dietary supplement maker, in an attempt to skirt civil and criminal charges, is taking aim at the Queen’s Medical Center and the state’s Department of Health over how they handled the sickened patients. Last year, a federal grand jury in Dallas, Texas where USPLABS is based, indicted the company’s top executives for conspiracy to commit wire fraud and for importing shipments from China using fake documents. Now the company is ... Read More

Feds find female libido drug hidden in dietary supplements

dietary supplements - pills, probiotics

Dietary supplements promoting sexual enhancement most often target men. In numerous cases, they are found to contain hidden drug ingredients including erectile dysfunction drugs like Viagra and Cialis. But a recent recall of dietary supplements issued by Organic Herbal Supply for supplements designed to boost female libido were found to contain undeclared flibanserin, a prescription medication sold under the brand name Addyi that was approved in late 2015 for the treatment of hypoactive sexual desire disorder in women. Food and Drug Administration (FDA) laboratory analysis on dietary supplements promoted for sexual enhancement has routinely turned up the presence of prescription-only ... Read More

Former FDA chief to testify on Xarelto makers’ conduct


In January 2015, former Food and Drug Administration (FDA) Commissioner David Kessler testified in a Philadelphia court that five years before Johnson & Johnson subsidiary Janssen Pharmaceuticals added warnings to its antipsychotic Risperdal regarding a side effect involving disfiguring breast growth in adolescent boys, the company was aware of its danger to minors. It was the first bellwether trial among thousands involving claims that Janssen tried to cover up Risperdal side effects. Kessler testified that Risperdal “probably or very likely” triggered breast growth in boys – a condition called gynecomastia. He backed up that claim by referencing a 2001 study ... Read More

DEA raids LA pharmacy over ‘off the charts’ opioid prescriptions

Opioid abuse - Shutterstock

Drug Enforcement Administration (DEA) officials raided a Chalmette, Louisiana, pharmacy about 10 miles east of New Orleans reportedly for dispensing opioids at a rate that was “off the charts,” making it one of the highest-prescribing pharmacies in the state, according to The Advocate. DEA authorities issued seizure warrants at Wilkinson Family Pharmacy and arrest warrants for the pharmacy’s owner Keith Wilkinson, and business partner. The agency worked in conjunction with the Sheriff’s office. The operation comes as neighboring New Orleans experienced a surge in accidental overdose deaths in 2016, for the first time surpassing murders in the parish. The problem ... Read More

FDA restricts use of codeine, tramadol in children, breastfeeding mothers


The Food and Drug Administration (FDA) is restricting the use of codeine and tramadol medicines, recommending against the use in children younger than 12, limiting the use in some older children, and discouraging the use in breastfeeding mothers due to serious risks including slowed or difficult breathing and death. Codeine and tramadol are a type of narcotic medicine called opioids. Codeine is used to treat pain and cough. Tramadol is a painkiller. Single-ingredient codeine and all tramadol-containing drugs are FDA approved only for use in adults. However, data shows that tramadol is being used in children and adolescents. In 2013, ... Read More

Talc litigation asks when to warn consumers of health risks

talc justice

An attorney analyzing the legal landscape for the Claims Journal used the talc litigation to examine the issue of failure to warn. He concluded that manufacturers and their insurers can’t assume that the argument that they are waiting on a scientific consensus about an alleged risk associated with their product will protect them from liability. In spite of the fact that scientists are still studying the effects of talc on the female reproductive system and that there is debate over how to interpret the decades of research that has already been done, three juries in 2016 found Johnson and Johnson to be liable ... Read More

J&J blames disappointing 1Q sales on Invokana, Xarelto performance


Johnson & Johnson’s recently reported first quarter earnings report dropped more than 3 percent on the day the news was announced, a rarity for a fairly stable stock, according to NASDAQ analysts. The consumer health care and pharmaceutical giant is blaming the weak first-quarter earnings on price discounting in certain sales channels, as well as competition for the underperformance of its pharmaceuticals. Specifically, sales of J&J’s type 2 diabetes drugs Invokana and Invokamet fell almost 16.8 percent in the U.S. due to lower prices. The company’s blood thinner Xarelto, manufacturered in partnership with Bayer, saw a slight increase in prescription share, ... Read More